| Investment Objective: |
Virtus Biotech Clinical Trials ETF seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Clinical Trials Index (the "Underlying Index"). Under normal market conditions, the Fund will invest not less than 80% of its assets in component securities of the Underlying Index. The Underlying Index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering ("lead drug") that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval. The Underlying Index is sponsored by LifeSci Index Partners, LLC (the "Index Provider"). The Index Provider utilizes a selection committee comprised of its employees that is responsible, pursuant to the rules included in the methodology for the Underlying Index, for making certain determinations for the Underlying Index. The Index Committee utilizes various public data sources to make determinations, including, but not limited to, Securities and Exchange Commission ("SEC") filings, public documents from the U.S. Food and Drug Administration ("FDA"), company press releases and official corporate websites. |
